Drug
APG101 clinical trials
Also written APG101, CAN008 and Asunercept.
- studies test it
- 9
- open now
- 0
- in phase 3
- 2
- first study started
- 2009
How studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 6
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 2
CANbridge Life Sciences Ltd. (3) · Apogenix GmbH (3) · University Hospital Heidelberg (1) · Apogenix AG (1) · Medical University of Vienna (1)
Often tested with
Tested in the same studies.
Alectinib (1) · RG7388 (1) · Atezolizumab (1) · HhAntag691 (1) · Temsirolimus (1) · Palbociclib (1) · Therapeutic Procedure (1) · Complementary or Alternative Medical Procedure (1)
Studies
Open first, then newest update. How each study uses APG101 is read from its arms, and is right about nine times in ten.
Testing it · 9
- NCT Neuro Master Match - N²M² (NOA-20)CompletedPhase 1/2University Hospital HeidelbergNCT03158389Written as APG101
- Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 DiseaseTerminatedPhase 3Apogenix GmbHNCT05639192Written as Asunercept
- Phase 2 Study of CAN008 in Subjects With GBMStatus unknownPhase 2CANbridge Life Sciences Ltd.NCT05447195Written as CAN008
- Asunercept in Patients With Severe COVID-19CompletedPhase 2Apogenix AGNCT04535674Written as Asunercept
- Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Status unknownPhase 2/3Medical University of ViennaNCT04351724Written as Asunercept 400mg
- To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)Status unknownPhase 2CANbridge Life Sciences Ltd.NCT03746288Written as CAN008
- A Study of CAN008 for Newly Diagnosed Glioblastoma MultiformeCompletedPhase 1CANbridge Life Sciences Ltd.NCT02853565Written as CAN008
- APG101 in Myelodysplastic SyndromeCompletedPhase 1Apogenix GmbHNCT01736436Written as Treatment with APG101
- APG101 in GlioblastomaCompletedPhase 2Apogenix GmbHNCT01071837Written as APG101
Codes
What other systems call APG101 · ClinicalTrials.gg INT006131
- MeSH (NLM) C574675APG101One source NLM
- UNII (FDA) F333OQQ9UVASUNERCEPTConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C574675 | APG101 | One source NLM |
| UNII (FDA) | F333OQQ9UV | ASUNERCEPT | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.